Evidence map›Paper›PMID 42466460›Full record

ArticleBMJ public health2026

'Why should I start medication when I am not feeling sick?' A qualitative study of refusal, initiation, completion and discontinuation of tuberculosis preventive treatment among people living with HIV in sub-Saharan Africa.

Lindiwe Tsope, Lucy Chimoyi, Audrey Kennar, Israel Rabothata, Solomon Sisay, Kenny Sithole, Nicole Kawaza, Tsitsi Apollo, Chlorata Gwanzura, Solomon Dressie and 5 more

Abstract read
In one paragraph

Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lindiwe TsopeImplementation Research Division, Aurum Institute, Johannesburg, South Africa.ORCID https://orcid.org/0009-0009-7069-796X
Lucy ChimoyiImplementation Research Division, Aurum Institute, Johannesburg, South Africa.
Audrey KennarJohns Hopkins University, Baltimore, Maryland, USA.
Israel RabothataImplementation Research Division, Aurum Institute, Johannesburg, South Africa.
Solomon SisayKNCV Tuberculosis Foundation, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0003-1965-2837
Kenny SitholeClinton Health Access Initiative, Harare, Zimbabwe.
Nicole KawazaClinton Health Access Initiative, Harare, Zimbabwe.
Tsitsi ApolloNational TB and Leprosy Program, Zimbabwe Ministry of Health and Child Care, Harare, Harare Province, Zimbabwe.
Chlorata GwanzuraNational TB and Leprosy Program, Zimbabwe Ministry of Health and Child Care, Harare, Harare Province, Zimbabwe.
Solomon DressieNational TB and Leprosy Program, Addis Ababa City Administration Health Bureau, Addis Ababa, Ethiopia.
Ahmed BedruKNCV Tuberculosis Foundation, Addis Ababa, Ethiopia.
Christiaan MulderDepartment of TB Elimination and Health System Innovations, KNCV Tuberculosis Foundation, The Hague, Netherlands.
Violet ChihotaGlobal Science, Aurum Institute, Johannesburg, South Africa.ORCID https://orcid.org/0000-0003-1444-9266
Christopher J HoffmannDepartment of Medicine, Johns Hopkins University, Baltimore, Massachusetts, USA.
Jill OwczarzakJohns Hopkins University, Baltimore, Maryland, USA.

Funding

Bill & Melinda Gates Foundation INV-006096
6 · The paper itself

Abstract

Introduction: Tuberculosis (TB) preventive treatment (TPT) is effective in preventing TB among people living with HIV (PLHIV). Patient experiences and preferences contribute to optimising the delivery cascade for TPT among PLHIV. We describe patient-level reasons for initiation, completion, refusal and discontinuation of 3HP (high-dose rifapentine (RPT) 900 mg plus isoniazid (INH) 900 mg weekly for 3 months) and INH in Ethiopia, South Africa and Zimbabwe. Methods: We conducted a total of 141 45-60 min in-depth interviews (IDIs) with adult PLHIV in Ethiopia (n=45), South Africa (n=45) Zimbabwe (n=51) between March and June 2022. Participants were attending routine HIV care in nine healthcare facilities and interviewed using a study-designed interview guide. The guide explored three categories: TB and TPT knowledge, reasons for TPT initiation and experiences of taking TPT and antiretroviral therapy (ART). Recordings were transcribed verbatim, translated and thematically analysed on MAXQDA using an abductive coding scheme incorporating the information-motivation-behavioural (IMB) skills model to understand reasons behind TPT uptake patterns. Results: Of the 141 participants, 28 were still on TPT, 66 completed, 22 discontinued and 25 refused to initiate TPT. The majority were female (88%, 124/141), with an average of 36 years. IMB constructs were reflected in participants' TPT uptake patterns, with illustrative quotes highlighting key patterns across the dataset. In relation to information, participants demonstrated knowledge of TPT and its benefits; however, there was confusion about the role of TPT in the absence of TB disease. Prior TB experiences, social support and engagements with healthcare workers were motivations for uptake. The main behaviours found included adoption of adherence strategies and use of medication reminders. Side effects, fears of pill burden and contraindications had negative outcomes for TPT uptake and completion. Conclusions: The findings underscore the need to enhance the understanding of TPT through targeted interventions at clinic and community levels. Strengthening these efforts may improve TPT uptake and completion rates.

Indexed as

HIVPreventive MedicinePublic HealthQualitative Research

Identifiers

PMID42466460
PMCPMC13374446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.